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ABSTRACT
The cellular prion protein, PrPC, is attached by
a glycosylphosphatidylinositol anchor to the outer
leaflet of the plasma membrane. Its misfolded iso-
form, PrPSc, is the causative agent of prion diseases.
Conversion of PrPC into PrPSc is thought to take
place at the cell surface or in endo-lysosomal or-
ganelles. Understanding the intracellular trafficking
of PrPC may therefore help elucidating the conver-
sion process. Here we describe a time-resolved flu-
orescence resonance energy transfer (FRET) assay
reporting membrane expression and real-time inter-
nalization rates of PrPC. The assay is suitable for
high-throughput genetic and pharmaceutical screens
formodulators of PrPC trafficking. Simultaneous ad-
ministration of FRET donor and acceptor anti-PrPC
antibodies to living cells yielded a measure of PrPC
surface density, whereas sequential addition of each
antibody visualized the internalization rate of PrPC
(Z’-factor > 0.5). RNA interference assays showed
that suppression of AP2M1, RAB5A, VPS35 and
M6PR blocked PrPC internalization, whereas down-
regulation of GIT2 and VPS28 increased it. PrPC
cell surface expression was reduced by downregula-
tion of RAB5A, VPS28 and VPS35, and enhanced
by silencing EHD1. These data identify a network of
proteins implicated in PrPC trafficking, and demon-
strates the power of this assay for identifying modu-
lators of PrPC trafficking.
The infectious agent causing prion diseases (1) is
a misfolded and aggregated isoform (PrPSc) of the
host-encoded cellular prion protein (PrPC). The pri-
mary translation product of PrPC is cotranslation-
ally translocated to the rough endoplasmic retic-
ulum (2), where it undergoes the addition of N-
linked oligosaccharide chains, the formation of an
intramolecular disulfide bond, and the attachment
of a glycosylphosphatidylinositol (GPI) anchor (3).
Distal sorting delivers PrPC to the plasmamembrane
where it resides in lipid rafts (4). Mature PrPC is then
recycled between the plasma membrane and the en-
docytic compartment (5).
Several processes have been reported to participate
in the endocytosis of PrPC (6–8). PrPC located in
lipid rafts may be internalized by caveolin/dynamin-
dependent endocytosis. PrPC is transported via
caveosomes to early endosomes or to lysosomes for
degradation. Alternatively, internalization of PrPC
may be mediated by a clathrin-dependent process
(9–11) whereby PrPC migrates to clathrin-coated
pits and is then transported to early endosomes.
Dynamin-independent endocytosis pathways may
also be involved. This process may be crucial for the
conversion of normal PrPC into PrPSc, as the con-
formational change seems to take place at the cell
surface and/or in the endocytic pathway. Real-time
measurements of PrPC internalization are therefore
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TR-FRET assay to detect PrPC membrane expression and internalization rates
of high interest and might eventually help identify-
ing therapeutic targets against prion diseases.
Fluorescence resonance energy transfer (FRET)-
based methods are widely used for the detection of
proteins (12) and to validate the proximity of pro-
teins in cells and tissues (13). FRET is a quantum-
mechanical process that transmits energy froman ex-
cited donormolecule to an acceptormolecule, result-
ing in red-shifted fluorescence emission by the latter
(14). Time-resolved FRETmethods based on the use
of Europium and allophycocyanin (APC) as donor
and acceptor, respectively, allows for homogeneous-
phase assays in the absence of background fluores-
cence (15). The long fluorescence lifetime of Eu-
ropium leads to a high signal-to-noise ratio and is
thus suited to high-throughput applications.
In the present study, we applied the FRET technol-
ogy to the development of a robust and sensitive
quantification assay for PrPC internalization. The
assay was designed to detect either cell surface ex-
pression of human PrPC or the internalization rate
of PrPC in living cells. For the detection of PrPC on
the cell surface, anti-PrP antibodies were added si-
multaneously, whereas the addition of the two FRET
components at different time points enabled themea-
surement of the endocytosis rate of surface-resident
PrPC by signal subtraction. Furthermore, we show
that this assay can be used to identify drugs and
genes that modulate PrPC surface expression and
PrPC endocytosis.
RESULTS
A homogeneous-phase TR-FRET im-
munoassay for PrP—We first developed a homoge-
neous TR-FRET immunoassay for the detection of
recombinant mouse PrP (residues 23-231; recPrP)
and PrPC in cell lysates. The principle of the assay
is shown in Figure 1. We tested several candidate
antibodies from an in-house PrP-targeted antibody
collection designated as POM antibodies (16), and
the previously characterized 3F4 antibody (17), for
their efficiency in this type of assay. Some of these
antibodies target linear epitopes in the N-terminal,
unstructured “flexible tail” of PrP, whereas others
recognize discontinuous, conformational epitopes
within the C-terminal globular domain of PrP (18–
20). Antibodies were coupled to the Europium
chelate (Eu) donor or the allophycocyanin (APC)
acceptor fluorophores. Various permutations of an-
tibodies in both donor and acceptor functions were
tested for their capability to detect recombinant and
normal PrPC in-solution. We predicted, and con-
firmed experimentally, that repetitive binding of the
POM2 antibody to the multiple octapeptide repeats
of PrP would allow for simultaneously utilization as
both donor and acceptor antibody (Figure 1).
Among the different antibody FRET pairs, the anti-
body combination POM1-Eu/POM2-APC exhibited
a satisfactory dynamic range over 3 logs (125 pg/ml
– 100 ng/ml) for the detection of recPrP diluted
in crude Hpl PrnP-/- cell lysate, an immortalized
hippocampal cell derived from Prnp-/- mice (21),
(Figure 2A) with signal linearity between 0.125 and
8 ng/ml (Figure 2B). A lower detection limit (LDL)
of < 0.125 ng/ml was determined for the detection
of recPrP.
We next assessed the specificity of the assay for
PrPC. We prepared serial dilutions of murine N2a
PK1 cell lysates in Hpl PrnP-/- cell lysates, followed
by FRET measurement using POM1-Eu/POM2-
APC for the detection of PrPC. PrPC was detected in
lysates across a wide dynamic range (16-500 µg/ml)
(Figure 2C) with excellent linearity (Figure 2D). A
lower detection limit (LDL) of < 20 µg/ml of crude
cell extract was determined for the detection of PrPC
in cells.
The performance of the TR-FRET-based immunoas-
say was further characterized by various validation
parameters and their defined acceptance criteria: the
coefficient of variance (%CV), the signal-to-noise
ratio (S/N), and the Z’ factor (22), a widely used
indicator for high-throughput suitability. A Z’ factor
greater than 0.5 is generally considered sufficient for
cell-based high-throughput campaigns. These data
are listed in Table 1.
Hence, the above data demonstrate a robust and
accurate performance of the assay with high speci-
ficity, which makes it suitable for the detection of
both recPrP and PrPC in high-throughput assays.
Design and development of cell surface PrP
FRET immunoassays — PrPC is present at the sur-
face of neurons and on various non-neuronal tissues
and leukocytes (23). To adapt our assay to human
cells, we first assessed PrPC expression in several cell
lines using a PrPC-specific ELISA (Figure S1). The
human lung epithelial cell line A549 and HeLa cells
2
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were identified as human cell lines with the highest
total PrPC expression. To identify the most effica-
cious antibody pair enabling detection of PrPC by
FRET, several POM antibodies were again screened
in various combinations of FRET donors and ac-
ceptors for A549 cells (Figure S2). The FRET pair
POM2-Eu/POM2-APC, which binds to the octapep-
tide repeats (Figure 1), yielded the highest FRET
signals within the POM antibody library. As this
antibody pair also yielded a good signal for HeLa
cells (Figure S2), we selected it for further use in the
assay.
We then determined the optimal cell number to be
used in the assay by plating different numbers of
HeLa and A549 cells, respectively, into 384-well
plates. On the following day, cells were washed
with ice-cold Tris-Krebs buffer and labeled with
POM2-Eu/POM2-APC for 30 min at 4°C. A cell
number-dependent FRET signal was detected in a
large dynamic range for both human cell lines with-
out washing (homogeneous time-resolved FRET
(HTRF) mode) which is more suited for automated
HTS applications and after washing out unbound
antibodies (TR-FRET mode) (Figure 3A), whereas
no signal was obtained for PrP-deficient cells (Hpl
PrnP-/-) used as negative control. These results con-
firmed the specificity of the assay.
For A549 cells, a linear dynamic range was found
between 500-4000 cells/well (R2 = 0.69) (Figure 3B
and C) in HTRF mode. The linear correlation was
improved (R2 = 0.94) in TR-FRETmode (Figure 3D
and E). Similar results were obtained when titrating
numbers of HeLa cells using the same antibody pair
(Figure 3F and H). Again, essentially linear dynamic
ranges were found from 500 to 8000 cells/well in the
HTRF mode (R2 = 0.90) and in the TR-FRET mode
(R2 = 0.98) (Figure 3G and I). For both cell lines
and in both measurement modes, 500 cells were
sufficient to generate a statistically reliable FRET
signal. Assay performance acceptance criteria of
Z’ factors >0.5, CV values <10% and S/N values
>8 were achieved for HeLa cells in the range of 8K
to 32K cells in TR-FRET and HTRF mode and for
A549 in the range of 2K to 32K cells in the TR-
FRET and 32K cells in the HTRF mode (Table 2).
These data validated the assay as a robust and accu-
rate assay for the detection of cell surface PrPC on
intact cells under these conditions.
Manipulation of human PrP cell sur-
face expression on living cells using HTRF and
TR-FRET—We then assessed the applicability of
the assay to the detection of cell-surface PrPC. 500
intact, viable cells were preincubated with varying
concentrations of unlabeled POM2 antibody. After
removing unbound POM2 by washing, cells were
incubated with labeled POM2-Eu/POM2-APC. Re-
sults in the HTRF (Figure 4A) and TR-FRET mode
(Figure 4B) showed an increase in the FRET sig-
nal intensity with decreasing concentrations of un-
labeled POM2 antibody, as expected from binding
site saturation by competing antibodies.
To control the level of PrPC cell surface expression
on intact cells, the GPI anchor of PrPC was enzy-
matically cleaved with phosphatidylinositol-specific
phospholipase C (PI-PLC). A549 cells were initially
labeled with POM2-Eu/POM2-APC and exposed to
different concentrations of PI-PLC. FRET signals of
cell-surface retained and released PrPC were mea-
sured after transferring the supernatant into a new
plate (Figure 4C and D). With increasing PI-PLC
concentrations, we found decreasing levels of sur-
face PrPC and elevated levels of PrPC in the super-
natant. To monitor cytotoxicity of PI-PLC exposure
on A549 cells, we established an alamarBlue® cell
viability assay (Figure S3). No effect of PI-PLC
treatment on A549 cell viability was detectable (Fig-
ure S3).
We next tested the performance of the assay in de-
tecting the pharmacological manipulation of PrPC
surface expression in living HeLa and A549 cells.
Cells were treated with 0-10 µg/ml brefeldin A
(BFA) diluted in 0.75% DMSO (24). BFA inhibits
the transport of proteins from the ER to the Golgi
apparatus, and thus reduces their display at the cell
surface. We found that a BFA concentration of 1
µg/ml in 0.75% DMSO decreased the PrPC expres-
sion level at the cell surface of about 66% in the
HTRF (Figure 4E) and about 75% in the TR-FRET
mode (Figure 4F) without affecting the cell viability.
Next, we investigated the applicability of our assay to
the genetic manipulation of the cell surface PrPC ex-
pression of intact A549 cells. We first used a siRNA
targeting the human PRNP gene. The PRNP siRNA
was also fully functional as shown by qPCR (Figure
S5) and had no toxic effects on the cells as moni-
tored by the alamarBlue assay (Figure S4). We found
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TR-FRET assay to detect PrPC membrane expression and internalization rates
that the siRNA efficiently downregulated the expres-
sion of PrPC on the surface of living A549 cells
in a concentration-dependent manner (p < 0.0001),
whereas scrambled siRNAs used as negative con-
trols had no significant effect on PrPC expression
(Figure 4G). Complete suppression was reached at a
concentration of 50-100 nM siRNA, as shown by a
comparison of the Net-FRET signal to those of Hpl
PrnP-/- deficient cells.
These data demonstrate that the assay can be ap-
plied to high-throughput pharmacological and ge-
netic PrPC cell surface manipulation screens.
PrP endocytosis measured by FRET— In a
next step, we modified the assay format towards a
PrPC endocytosis assay to assess its suitability for
the identification of modifiers controlling the cell
surface expression and endocytosis of PrPC. The
principle of the modified assay is shown in Figure
5A. In a first set of experiments, various antibody
combinations and cell culture conditionswere tested.
Satisfactory results were obtained with A549 cells
cultured in DMEM medium (without phenol red,
antibiotics and FBS) during endocytosis using the
antibody combination POM2-Eu/POM2-APC. Af-
ter labeling A549 cells with POM2-Eu, free antibod-
ies were removed by washing and endocytosis was
induced at 37°C after 5 minutes pre-incubation. At
specified time points (t = 0-70min) POM2-APCwas
added to different wells (15 time points à 6 wells).
After the last addition of POM2-APC at 70 min,
FRET signals were measured for all wells (Figure
5B). A gradual decrease of Eu-POM2-labeled cell
surface PrPC was observed over time; the decrease
was almost linear between 0-30 min (R2 = 0.79; Fig-
ure 5C). Similar data were also obtained for HeLa
cells (Figure S6A). We found that PrPC undergoes
endocytosis also when antibodies are added in a re-
versed order (Figure S6B). The endocytosis rate of
PrPC was calculated according to the uptake formula
(see Experimental Procedure). After 30 minutes of
incubation, 80% of cell surface-resident PrPC was
endocytosed (Figure 5D) which is in agreement with
previously reported half-times for PrPC internaliza-
tion (5).
Pharmacological blocking of PrP endo-
cytosis pathways—We then used the endocyto-
sis assay to gauge the effects of compounds
inhibiting clathrin-mediated endocytosis (chlor-
promazine/CPZ) and clathrin-independent uptake
(methyl-beta-cyclodextrin/MbetaCD) on internal-
ization of PrPC in A549 cells (25). CPZ causes
clathrin lattices to assemble on endosomal mem-
branes and prevents the assembly of coated pits at
the plasma membrane (26), whereas MbetaCD se-
lectively extracts cholesterol from the plasma mem-
brane (27). Cells were pre-treated for 30 min with
CPZ or MbetaCD in a dose-dependent manner and
subsequently labeled with POM2-Eu (Figure 6). Af-
ter 30 min of incubation at 37°C, POM2-APC was
added and inhibition of PrPC uptake was assayed
by TR-FRET. Figure 6A represents the internaliza-
tion of PrPC in A549 cells in the presence of CPZ.
CPZ decreased the entry of PrPC in A549 cells in
a dose-dependent manner. A concentration of 0.28
µM CPZ was sufficient to block clathrin-mediated
endocytosis of PrPC without affecting the cell via-
bility of A549 cells as determined in an alamarBlue
assay (Figure 6B). On the other hand, a concentra-
tion of 5 mMMbetaCD inhibited the uptake of PrPC
without any toxic effect on cell viability as moni-
tored by an alamarBlue assay (Figure 6C and D).
The combination of CPZ and any inhibitor block-
ing clathrin-mediated internalization did not cause
any further decrease in the uptake of PrPC. These
data support recent findings on MbetaCD in initi-
ating PrPC endocytosis (28) and the importance of
cholesterol for the endocytosis of PrPC (29) as well
as the inhibitory effect of CPZ on the internalization
of PrPC (30).
Identification of genes that differently im-
pact cell surface expression and endocytosis of
PrP—Next, the potential of the endocytosis assay
towards genetic manipulations was tested by using
seven hand-picked small interfering RNAs (siRNA)
targetingmajor proteins of themembrane-trafficking
machinery and their downstream organelles (Figure
7 and Table 3). We expected that some of these
siRNAs would modify the endocytosis rate and cell-
surface expression of PrPC, resulting in a reduced
FRET signal. The efficacy of PRNP knock-down
was again controlled using a siRNA targeting the
PRNP gene, whereas untreated cells acted as a neg-
ative control. The functionality of the siRNAs was
verified by quantitative PCR (Figure S5) and po-
tential toxic effects of the siRNAs to the cells were
controlled by performing cell viability assays (Fig-
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ure S4).
We found that the knockdown of the small GTPase
protein Rab5a, which controls clathrin-dependent
endocytosis (31–33) and early endosome dynamics
(34), significantly reduced the cell surface expres-
sion (t0) and strongly blocked the endocytosis (t0-
t30) of PrPC (Figure 7 and Table 4). Also AP2M1
(AP-2 adaptor protein), a gene involved in clathrin-
dependent endocytosis pathways (35) blocked the
uptake of PrPC. Other genes, such as M6PR
(Mannose-6-phosphate receptor) (36) and VPS35
(vacuolar protein sorting 35 homolog) (37), which
are involved in retrograde transport of proteins from
endosomes to the trans-Golgi network, also sup-
pressed the internalization of PrPC. Moreover, the
VPS35 protein was recently shown to reduce the
expression of alpha-synuclein in a prion-like seed-
ing model in transgenic mice, thus protecting them
from neurodegeneration (38). We also tested EHD1,
a gene that encodes the EH domain-containing pro-
tein 1 that is involved in endocytosis (39). Sup-
pression of EHD1 slightly increased the cell surface
expression level (t0) of PrPC (Figure 7 and Table 4
without affecting endocytosis. For VPS28, a gene
that encodes the vacuolar protein sorting-associated
protein 28 homologue involved in endosomal sorting
of cell surface receptors (40), an increased endocyto-
sis rate and reduced PrPC cell surface expressionwas
found. Silencing of GIT2, a gene that encodes the
ARFGTPase-activating protein GIT2 (41) increased
the uptake of PrPC without affecting PrP cell surface
level (Figure 7). Hence, we were able to identify
a number of genes involved in clathrin-dependent
internalization of PrPC and its trafficking to early
endosomes. This demonstrates the potential of the
assay for comprehensive high-throughput screens of
compounds and genes that target the internalization
and endocytosis pathway of PrPC.
DISCUSSION
The exposure of PrPC at the surface of tar-
get cells is a precondition to prion replication and
to prion neurotoxicity (42, 43). Several studies have
shown that masking PrPC with antibodies (44) or
suppressing its expression with siRNA (45) can re-
duce prion replication and prolong the life of prion-
infected mice. Therefore, an in-depth understanding
of the factors controlling PrPC expression at the cell
surface may pave the way to treating human prion
diseases.
High-throughput screening platforms to identify
modulators of the transcription, translation and pro-
tein cycling turnovers that regulate cellular PrP may
point to druggable targets, which could be used to se-
lectively reduce human PrPC in the treatment of CJD
patients (46). Being a single-pot method, FRET is
suitable to high-throughput assay formats. However,
FRET does not allow for the extensive signal ampli-
fication afforded by enzyme-linked immunoassays.
We therefore wondered whether FRET-based PrPC
detection in high-density microtiter plates would
provide the analytical power necessary for this type
of assay. Indeed, the assays described here provide
high scalability, high specificity, a wide dynamic
range and sensitive detection that compareswellwith
enzyme-linked immunosorbent assays (47). More-
over, the assays exhibit broad dynamic ranges and
were found to be highly target-specific by spiking,
competition and blocking experiments, and required
only nanomolar quantities of antibodies. The large
detection window and the Z’ factor finally allowed
us to identify compounds and genes that differently
impact the cell surface expression and endocytosis
rate of normal PrPC, thus demonstrating the practi-
cality of the FRET assays for HTS applications in a
384-well format (46, 48).
We then studied the applicability of the FRET-based
immunoassays for the simultaneously identification
of compounds and genes that differently affect the
level and internalization rate of cell surface PrPC.
We first studied the internalization of endogenously
expressed human PrPC on cells. A cell surface half
life time of about 25 min of PrPC was determined –
which is in agreement with previous results (5). No
PrPC was detectable in the culture medium during
the endocytosis experiment, confirming that PrPC is
mainly endocytosed rather than released from the
cell surface. We also observed no loss of FRET
signal intensity over the whole time period (75 min)
of the cell-surface PrPC FRET assay, indicating that
the PrP-mAbs-Eu complex is stable in our experi-
mental settings. We further conclude from the good
agreement of our internalization rate with previously
published results (5) that the stability of the PrP-
mAbs-Eu complex is also not significantly affected
in endosomal compartments and that the binding
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of POM2, even if it might modulate interactions of
PrPC with other membrane proteins had no signif-
icant effect on PrP endocytosis. In control experi-
ments, MbetaCD and CPZ inhibited endocytosis of
PrPC without affecting cell viability at the chosen
concentrations as already reported earlier (31, 49).
We tested the suitability of the FRET-based endo-
cytosis assay for the identification of cell surface
and endocytosis modulators of PrPC. The siRNAs
repressing RAB5A andAP2M1 (encoding the µ sub-
unit of the AP-2 complex) showed the strongest in-
hibition of PrPC internalization. These data sug-
gest clathrin-mediated endocytosis of PrPC, as hy-
pothesized by earlier studies showing that AP-2
co-localizes with PrPC (10). Rab5a suppression
brought about a strong reduction in PrPC cell surface
expression and completely blocked the endocytosis
of PrPC after 30 minutes. Similar results were re-
ported by Magalhaes et al. (46), who showed that
green fluorescent protein (GFP)-tagged PrPC, but
not GFP-GPI, is endocytosed via Rab5-containing
early endosomes (50). Knock-down of VPS35 and
M6PR also suppressed endocytosis of PrPC, albeit
less prominently. This suggests additional physical
or epistatic interactions of these geneswith PrPC. Fi-
nally, knock-down of VPS28 resulted in an increased
uptake of PrPC by reducing PrPC cell surface expres-
sion.
In summary, we provide proof-of-concept for FRET-
based assays that are suited as high-throughput
screening platforms to identify small molecules or
compounds that genetically or pharmacologically
block or induce PrPC endocytosis. The assays can
be utilized to measure the internalization rate, to
characterize the different endocytosis pathways and
to perform large-scale RNAi screenings to identify
genes regulating PrPC expression, biosynthesis and
endocytosis. The knowledge gained from these ex-
periments is likely to lead to the discovery of novel
compounds for the treatment of prion diseases, and
perhaps even for other protein misfolding and ag-
gregation diseases which share pathways with those
active in prion diseases.
EXPERIMENTAL PROCEDURES
Cell Culture—N2a PK1 (a subclone of neu-
roblastomaN2a cells) andHpl PrnP-/- cells (21)were
cultured in 75-cm2 tissue culture flasks in OptiMEM
medium supplemented with 10% (vol/vol) fetal
bovine serum (FBS) and 1%penicillin/streptomycin.
Human HeLa and A549 cells were cultured in
DMEM medium supplemented with 10% (vol/vol)
fetal bovine serum and 1% penicillin/streptomycin.
In FRET experiments, all cell lines were cultured
in medium without FBS, antibiotics and phenol red.
To determine cell numbers and cell viability, re-
suspended cells were stained with trypan blue and
counted in a Neubauer chamber.
FRET Antibody Labeling—Monoclonal
POM antibodies were labeled in-house for FRET
applications. The donor fluorophore was Eu-
ropium chelate (Eu-W1024 ITC chelate, AD0096,
PerkinElmer). Coupling to proteins occurs at alka-
line pH via reaction of lysine residues and free N
termini with the aromatic isothiocyanate group of
the Europium chelate. To remove possible contam-
inant interfering with labeling, antibodies were dia-
lyzed overnight in 1 ml of 100 mM sodium carbon-
ate buffer (Na2CO3, pH 9-9.3). Dialysis cassettes
(Slide-A-Lyzer®, Thermo scientific) with a 7 kDa
cut-off were used. Dialysis was done under stirring
in a volume of 2 l of 100 mM Na2CO3 pH 9-9.3
at 4°C overnight. Dialysis buffer was changed after
4-6 h.
Antibodies were concentrated by Centricon concen-
trators (Millipore). Protein concentration was ad-
justed by the Bradford or BCA assay to a concen-
tration of about 5 mg/ml. A molar excess of 24x
of Europium chelate over IgG was added into the
protein solution on ice and incubated in 100 mM
Na2CO3 over night at 4°C. Separation of the labeled
protein from non-reacted chelate was performed by
size exclusion chromatography (Superdex 200 col-
umn, GE Healthcare). Elution from column was
done with 50 mM Tris-HCl pH 7.8 + 0.9% sodium
chloride. Sample fractions of 500 µl were collected.
Fractions were pooled and concentrated with Mi-
cron centrifugal filters (Amicon). Labeling ratio
and concentration of labeled proteins were assessed
by an Europium standard solution (Perkin Elmer)
and NanoDrop measurement, respectively. Allo-
phycocyanin (APC,AnaTagTMLabelingKit 72111,
Anaspec) was used as acceptor fluorophore for con-
jugation to POM antibodies. Maleimide groups of
APC react with sulfhydryl groups on the target anti-
body to form a covalent bond. POM antibodies were
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concentrated to 2-10 mg/ml in a volume of 100 µl
with Centricon concentrators (Millipore). Antibod-
ies were reduced with 20 µl dithiothreithol (DTT)
per ml of IgG solution for 30 min without agita-
tion at room temperature. Depending on reaction
volume, reduced antibodies were desalted either by
spin or gravity columns. Protein concentration was
assessed by NanoDrop measurement. For the con-
jugation reaction, 1.5 mg of activated APC per mg
reduced IgG was added to the reduced antibodies
solution and incubated for 1 h at room temperature
with agitation. Free thiol groups were blocked by
adding DMSO and NEM for 30 min at room tem-
perature. To remove free APC molecules from an-
tibody solution, reaction mixture was purified via a
protein G Sepharose column (Sigma). The column
was washed with water and 10 volumes of 20 mM
phosphate buffer pH 7 to equilibrate. Samples were
added and washed with five volumes 20 mM phos-
phate buffer pH 7. Flow-through was collected. The
columnwas eluted with 0.1M glycine pH 2.3 and di-
luted with 1 M Tris HCl (pH 8). APC-labeled POM
antibodies were characterized by NanoDrop (A280
and A650).
Time-resolved Fluorescence Measure-
ments—The Wallac EnVision multilabel reader
(PerkinElmer) was used for all FRET experiments
using protocols installed by the manufacturer. A
nitrogen laser device (337 nm) excites Eu which
activates APC in a distance-dependent manner. Flu-
orescence emissions were monitored both at 615 nm
for Eu and at 665 nm for APC. An integration time
of 100 or 400 µs was used after a time delay ranging
from 50 to 100 µs to remove short-lived background
signals.
Data Analysis—The distance-dependent
energy transfer between the chromophore-
conjugated antibodies determines the FRET signal
intensity in the presence of PrP and is henceforth
reported as “net FRET” signal. Net FRET sig-
nals are the number of APC counts depending on
FRET events and calculated by using the following
equation:
NetFRETsignal =
(counts − APCblank)APC − P(counts − bu f f er)Eu,
(1)
where counts are the raw FRET-dependent signals in
APC and Eu channel, respectively, minus the back-
ground fluorescence. The proportionality factor P
defines spectral overlap compensations and is mea-
sured by the equation:
P =
(Eublank − bu f f er)APC
(Eublank − bu f f er)Eu . (2)
Eublank and APCblank correspond to all reagents ex-
cept Eu or APC in Eu or APC channel, respectively.
In addition, cells deficient of PrP were used as neg-
ative controls.
To show the reliability of FRET-based immunoas-
says for high-throughput applications, the statistical
parameter Z’ factor (22) was calculated by the for-
mula:
Z ′ = 1 − 3 ∗ SDpos + 3 ∗ SDneg|µpos − µneg | (3)
where SD is the standard deviation and µ is
the mean of positive and negative controls. An as-
say is considered to be excellent for high-throughput
applications if the Z’ factor is equal or superior to
0.5.
PrP Cell Surface FRET Assay—Cells were
plated one day before into 96-well or 384-well mi-
crotiter plates (Perkin Elmer) in cell culture medium
without phenol red at the desired density. Cells
were washed once and FRET antibody labeling was
performed at 4°C containing 1 nM Eu-labeled and
5 nM APC-labeled antibodies in Tris-/Krebs buffer
(20 mM Tris pH 7.4, 118 mM NaCl, 5.6 mM glu-
cose, 1.2 mM KH2PO4, 1.2 mM MgSO4, 4.7 mM
KCl, 1.8 mM CaCl2, 1% BSA). FRET signals were
measuredwith theWallacEnVision reader (homoge-
neous time-resolved (TR)-FRET assay) with a time
delay of approximately 100 µ seconds between the
excitation and fluorescence measurement. There-
after, plates were washed with Tris-/Krebs buffer
and the FRET signal was measured again (TR-FRET
assay). Pharmacological treatment of cells was per-
formed with brefeldin A diluted in DMSO, for 18 h
incubation at 37°C. DMSO concentration was kept
constant at 0.75%. Cells were washed once with
ice-cold Tris-/Krebs buffer and labeled with FRET
antibodies as mentioned above. Enzymatic treat-
ment of cells was done with PI-PLC. PI-PLC was
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dialyzed in PBS overnight and protein concentra-
tion was assessed by the Bradford assay (BioRad).
Digestion was carried out either at 4°C or at 37°C
for 1 h during shaking (450 rpm). Supernatant was
transferred into a new plate and medium and cells
were labeled with FRET antibodies. The neuronal
Hpl PrnP-/- cell line was used as negative control for
assay development and optimization.
PrP Endocytosis FRET Assay —Cells were
plated and cultured for one day in 96- or 384-well
microtiter plates (Perkin Elmer) at the desired den-
sity. Cells were washed once and labeled with 1 nM
Eu-labeled POM antibodies in Tris-/Krebs buffer for
30 min at 4°C. After washing out unbound antibod-
ies, cells were pre-incubated for 5 minutes at 37°C.
At different time intervals, 5 nM of APC-labeled an-
tibodies were added in cell culture medium without
phenol red. FRET signals were measured with a
Wallac EnVision reader in the homogeneous FRET
assay mode or after a washing step in the TR-FRET
mode. The internalization rate of PrPC was calcu-
lated with the following equation:
Uptake =
(FRETPrPC
t=0)−(FRETPrPCt=x)
(FRETcellsur f acePrPCt=0)
(4)
To suppress PrPC endocytosis, A549 cells were
treated with ascending doses of chlorpromazine
(CPZ) or methyl-beta-cyclodextrin (MbetaCD), and
subsequently labeled with POM2-Eu. After 30 min
of incubation at 37°C POM2-APC was added and
inhibition of PrPC uptake was assayed by TR-FRET.
siRNA Treatment—To transfect siRNA into
mammalian cells, LipofectamineTM 2000 (Invit-
rogenTM) was utilized. One day before trans-
fection, 2500 cells in 80 µl DMEM cell culture
medium without antibiotics were seeded into a
96-well plate per well. SiRNA:LipofectamineTM
2000 complexes were prepared as follows: 5 µl
siRNA (1 µM) was diluted in 5 µl pre-warmed
DMEM cell culture medium without serum and
antibiotics and mixed gently. 0.1 µl Lipofec-
tamineTM 2000 was diluted in 9.9 µl pre-warmed
DMEM cell culture medium without serum and an-
tibiotics. After an incubation of 5 min at room
temperature, the diluted LipofectamineTM 2000
was combined with the diluted siRNA. To allow
formation of siRNA:LipofectamineTM 2000 com-
plexes, the combined solutions were mixed and in-
cubated for 20 min at room temperature. 20 µl
of siRNA:LipofectamineTM 2000 complexes were
added to eachwell of the 96-well plate and cells were
cultured at 37°C in a CO2 incubator for 72 h.
Quantitative PCR—Cell cultures were pre-
pared and incubated as stated above. Cells were
washed once with PBS and total RNA was extracted
using the RNeasy® mini kit (Qiagen) according to
the manufacturer’s protocol. RNA concentration
and purity was determined by NanoDrop measure-
ments. cDNA was synthesized from 0.5 µg to-
tal RNA with QuantiTect reverse transcription kit
(Qiagen) using random hexamers according to the
manufacturer’s protocol. Before cDNA synthesis,
genomic DNA was eliminated. Successful cDNA
synthesis and contamination of total RNA with ge-
nomic DNA was tested by PCR with primer specific
for GAPDH. Quantitative real-time PCR was per-
formed using the SYBR Green master mix (Applied
Biosystems) on an ABI Prism VIIA7 sequence de-
tector (PerkinElmer). Fold regulationwas calculated
relative to untreated cells after normalization to the
GAPDH signal. The following primer pairs were
used: VPS28 sense (NM_16208): 5’–TTG TTC
CCA GGG GCT CCT AT-3’, antisense: 5’–ATC
TTC CCG ACC GCG AG-3’. RAB5A sense
(NM_004162): 5’-TTAGAAAAGCAGCCCCAA
TG-3’, antisense 5’-GTA CTT CTG GGA GAG
TCC GC-3’. AP2M1 sense (NM_004068): 5’-AAT
CAT GGC GGC AGA TCA GT-3’, sense 5’-ATC
TTG GGA TCC GGA GAG TG-3’. GIT2 sense
(NM_014776): 5’- AGA CAA ATC CAG GCT
GCT GT-3’, antisense 5’-GCG CCT CGT GGA
AAT ACA GT-3’. EHD1 sense (NM_006795): 5’-
AAG AGC AGG ATG ATG CGG T-3’, antisense
5’-CCT GTC TGG AGA GAA GCA GC-3’. M6PR
sense (NM_002355): 5’-ATT CTC TCA CTG CCA
CAGCC-3’, antisense 5’-TGGCTACTCCAGTTT
CCC AC-3’. VPS35 sense (NM_018206): 5’-CAC
TGA TAG TCT GGT GGG CA-3’, antisense 5’-
CAGCTTACCAGCTGGCTTTT-3’. PRNP sense
(NM_000311): 5’-AGT GTT CCA TCC TCC AGG
C-3’, antisense 5’-GAG CTT CTC CTC TCC TCA
CG-3’. GAPH sense (NM_002046): 5’-CAT GAG
AAG TAT GAC AAC AGC CT, antisense 5’-AGT
CCT TCC ACG ATA CCA AA GT-3’.
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Cell Viability Assay—The alamarBlue®
assay (Invitrogen) was utilized to assess cell via-
bility according to the manufacturer’s protocol. All
experiments were performed in cell culture medium
without antibiotics and phenol red. Cells were in-
cubated with the alamarBlue dye at 37°C and the
fluorescence intensity was measured with a plate
reader after 1-6 hrs.
Acknowledgments: We thank Irina Abakumova and Clemence Tournaire for technical help. AA is the
recipient of an Advanced Grant of the European Research Council, a European Union Framework 7 Grant
(NEURINOX), the Swiss National Foundation, the Clinical Research Priority Programs “Small RNAs”
and “Human Hemato-Lymphatic Diseases”, the Swiss Initiative in Systems Biology, SystemsX.ch (PrionX,
SynucleiX), and the Novartis Research Foundation. SH is the recipient of the Swiss Initiative in Systems
Biology, SystemsX.ch (SynucleiX) and the commission innovations of the University Hospital of Zurich. LP
is the recipient of a Consolidator Grant of the Swiss National Science Foundation, the University of Zurich
Research Priority Program in Systems Biology, and the Swiss Initiative in Systems Biology, SystemsX.ch
(LipidX, PrionX). PL is the recipient of the Swiss National Science Foundation (PP00P3_157531).
Conflict of interest: The authors declare that they have no conflicts of interest with the contents of this
article.
Author contributions: BAB designed, performed, analyzed the experiments and wrote the initial draft of
the paper. RM provided technical assistance. PL, LP designed the experiments. SH and AA conceived,
coordinated and designed the study, analyzed data and wrote the paper. All authors analyzed and reviewed
the results and approved the final version of the manuscript.
9
 at U
ZH
 H
auptbibliothek / Zentralbibliothek Zuerich on A
pril 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
TR-FRET assay to detect PrPC membrane expression and internalization rates
REFERENCES
1. Aguzzi, A. and Calella, A, M. (2009) Prions: protein aggregation and infectious diseases, Physiol
Rev. 89(4), 1105–52.
2. Prusiner, S, B. (2004) Prion biology and diseases volume 1050, Cold spring harbor laboratory
press New York
3. Prusiner, S, B., Scott, M, R., DeArmond, S, J., and Cohen, F, E. (1998) Prion protein biology, Cell
93(3), 337–348.
4. Taylor, D, R. and Hooper, N, M. (2007) The low-density lipoprotein receptor-related protein 1
(lrp1) mediates endocytosis of the cellular prion protein, Biochem. J. 402(1), 17–23.
5. Shyng, S, L., Huber, M, T., and Harris, D, A. (1993) A prion protein cycles between cell surface
and an endocytic compartment in cultured neuroblastoma cells, J Biol Chem 268(21), 15922–8.
6. Harris, D, A. (2003) Trafficking, turnover and membrane topology of prp, Br Med Bull. 66, 71–85.
7. Prado, M, A., Alves-Silva, J., Magalhâes, A, C., Prado, V, F., Linden, R., Martins, V, R., and
Brentani, R, R. (2004) Prpc on the road: trafficking of the cellular prion protein, J Neurochem.
88(4), 769–81.
8. Campana, V., Sarnataro, D., and Zurzolo, C. (2005) The highways and byways of prion protein
trafficking, Trends Cell Biol 15(2), 102–11.
9. Shyng, S, L., Lehmann, S., Moulder, K, L., and Harris, D, A. (1995) Sulfated glycans stimulate
endocytosis of the cellular isoform of the prion protein, prpc, in cultured cells, J Biol Chem
270(50), 30221–9.
10. Sunyach, C., Jen, A., Deng, J., Fitzgerald, K, T., Frobert, Y., Grassi, J., McCaffrey, M, W.,
and Morris, R. (2003) The mechanism of internalization of glycosylphosphatidylinositol-anchored
prion protein, EMBO J 22(14), 3591–601.
11. Taylor, D, R., Watt, N, T., Perera, W, S., and Hooper, N, M. (2005) Assigning functions to
distinct regions of the n-terminus of the prion protein that are involved in its copper-stimulated,
clathrin-dependent endocytosis, J Cell Sci 118(Pt 21), 5141–53.
12. Morrison, L, E. (1988) Time-resolved detection of energy transfer: theory and application to
immunoassays, Anal Biochem. 174(1), 101–20.
13. Jares-Erijman, E, A. and Jovin, T, M. (2003) Fret imaging, Nat Biotechnol 21(11), 1387–95.
14. PR, S. (2000) The renaissance of fluorescence resonance energy transfer, Nat Struct Biol 7(9),
730–4.
15. Bazin, H., Trinquet, E., and Mathis, G. (2002) Time resolved amplification of cryptate emission: a
versatile technology to trace biomolecular interactions, J Biotechnol 82(3), 233–50.
16. Polymenidou, M., Moos, R., Scott, M., Sigurdson, C., Shi, Y, Z., Yajima, B., Hafner-Bratkovic, I.,
Jerala, R., Hornemann, S., Wuthrich, K., Bellon, A., Vey, M., Garen, G., James, M, N., Kav, N., and
Aguzzi, A. (2008) The pom monoclonals: a comprehensive set of antibodies to non-overlapping
prion protein epitopes, PLoS One 3(12), –.
17. Bolton, D, C., Seligman, S, J., Bablanian, G., Windsor, D., Scala, L, J., Kim, K, S., Chen, C, M.,
Kascsak, R, J., and Bendheim, P, E. (1991) Molecular location of a species-specific epitope on the
hamster scrapie agent protein, J Virol 65(7), 3667–75.
18. Hornemann, S., Korth, C., Oesch, B., Riek, R., Wider, G., Wüthrich, K., and Glockshuber, R.
(1997) Recombinant full-length murine prion protein, mprp(23-231): purification and spectro-
scopic characterization, FEBS Lett 413(2), 277–81.
19. Riek, R., Hornemann, S., Wider, G., Billeter, M., Glockshuber, R., and Wüthich, K. (1996) Nmr
structure of the mouse prion protein domain prp(121-231), Nat. 382(6587), 180–2.
20. Wüthrich, K. and Riek, R. (2001) Three-dimensional structures of prion proteins, Adv Protein
Chem 57, 55–82.
21. Sakudo, A., Onodera, T., and Ikuta, K. (2007) Prion protein gene-deficient cell lines: powerful
10
 at U
ZH
 H
auptbibliothek / Zentralbibliothek Zuerich on A
pril 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
TR-FRET assay to detect PrPC membrane expression and internalization rates
tools for prion biology, Microbiol Immunol 51(1), 1–13.
22. Zhang, J, H., Chung, T, D., and Oldenburg, K, R. (1999) A simple statistical parameter for use in
evaluation and validation of high throughput screening assays, J Biomol Screen 4(2), 67–73.
23. Aguzzi, A. and Polymenidou, M. (2004) Mammalian prion biology: one century of evolving
concepts, Cell 116(2), 313–27.
24. Nebenführ, A., Ritzenthaler, C., and Robinson, D, G. (2002) Brefeldin a: deciphering an enigmatic
inhibitor of secretion, Plant Physiol 130(3), 1102–8.
25. Vercauteren, D., Vandenbroucke, R., Jones, A, T., Rejman, J., Demeester, J., De Smedt, S, C.,
Sanders, N, N., and Braeckmans, K. (2010) The use of inhibitors to study endocytic pathways of
gene carriers: optimization and pitfalls, Mol Ther 18(3), 561–9.
26. Wang, L, H., Rothberg, K, G., and Anderson, R, G. (1993) Mis-assembly of clathrin lattices on
endosomes reveals a regulatory switch for coated pit formation, J Cell Biol 123(5), 1107–17.
27. Klein, U., Gimpl, G., and Fahrenholz, F. (1995) Alteration of the myometrial plasma membrane
cholesterol content with beta-cyclodextrin modulates the binding affinity of the oxytocin receptor.
biochemistry, Biochem. 34(42), 13784–93.
28. Luo, K., Li, S., Xie, M., Wu, D., Wang, W., Chen, R., Huang, L., Huang, T., Pang, D., and Xiao, G.
(2010) Real-time visualization of prion transport in single live cells using quantum dots, Biochem.
Biophys Res Commun 394(3), 493–7.
29. Rodal, S, K., Skretting, G., Garred, O., Vilhardt, F., van Deurs, B., and K, S. (1999) Extraction of
cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles,
Mol Biol Cell 10(4), 961–74.
30. Sarnataro, D., Caputo, A., Casanova, P., Puri, C., Paladino, S., Tivodar, S, S., Campana, V.,
Tacchetti, C., and Zurzolo, C. (2009) Lipid rafts and clathrin cooperate in the internalization of prp
in epithelial frt cells, PLoS One 4(6), –.
31. Lanzetti, L., Rybin, V., Malabarba, M, G., Christoforidis, S., Scita, G., Zerial, M., and Di Fiore, P,
P. (2000) The eps8 protein coordinates egf receptor signalling through rac and trafficking through
rab5, Nat. 408(6810), 374–7.
32. Martinu, L., Santiago-Walker, A., Qi, H., and Chou, M,M. (2002) Endocytosis of epidermal growth
factor receptor regulated by grb2-mediated recruitment of the rab5 gtpase-activating protein rn-tre,
J Biol Chem 277(52), 50996–1002.
33. McLauchlan, H., Newell, J., Morrice, N., Osborne, A., West, M., and Smythe, E. (1998) A novel
role for rab5-gdi in ligand sequestration into clathrin-coated pits, Curr Biol 8(1), 34–45.
34. Stenmark, H., Valencia, A., Martinez, O., Ullrich, O., Goud, B., and Zerial, M. (1994) Distinct
structural elements of rab5 define its functional specificity, EMBO J 13(3), 575–83.
35. Boucrot, E., Saffarian, S., Zhang, R., and Kirchhausen, T. (2010) Roles of ap-2 in clathrin-mediated
endocytosis, PLoS One 5(5), –.
36. Le Borgne, R. and Hoflack, B. (1997) Mannose 6-phosphate receptors regulate the formation of
clathrin-coated vesicles in the tgn, J Cell Biol 137(2), 335–45.
37. Bonifacino, J, S. and Hurley, J, H. (2008) Retromer, Curr Opin Cell Biol 20(4), 427–36.
38. Dhungel, N., Eleuten, S., Li, L., Kramer, N, J., Chartron, J, W., Spencer, B., Kosberg, K., Fields,
J, A., Stafa, K., Adame, A., Lashuel, H., Frydman, J., Shen, K., Masliah, E., and Gitler, A. (2015)
Parkinson’s disease genes vps35 and eif4g1 interact genetically and converge on alpha - synuclein,
Neuron 85(1), 76–87.
39. Rainey, M, A., George, M., Ying, G., Akakura, R., Burgess, D, J., Siefker, E., Bargar, T., Doglio,
L., Crawford, S, E., Todd, G, L., Govindarajan, V., Hess, R, A., Band, V., Naramura, M., and
Band, H. (2010) The endocytic recycling regulator ehd1 is essential for spermatogenesis and male
fertility in mice, BMC Dev Biol 10(37), 328–42.
40. Bishop, N. and Woodman, P. (2001) Tsg101/mammalian vps23 and mammalian vps28 interact
11
 at U
ZH
 H
auptbibliothek / Zentralbibliothek Zuerich on A
pril 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
TR-FRET assay to detect PrPC membrane expression and internalization rates
directly and are recruited to vps4-induced endosomes, J Biol Chem 276(15), 11735–42.
41. Premont, R, T., Perry, S, J., Schmalzigaug, R., Roseman, J, T., Xing, Y., and Claing, A. (2004) The
git/pix complex: an oligomeric assembly of git family arf gtpase-activating proteins and pix family
rac1/cdc42 guanine nucleotide exchange factors, Cell Signal 16(9), 1001–11.
42. Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y., Marino, S., Weiss-
mann, C., and Aguzzi, A. (1996) Normal host prion protein necessary for scrapie-induced neuro-
toxicity, Nat. 379(6563), 339–43.
43. Sonati, T., Reimann, R, R., Falsig, J., Baral, P, K., O’Connor, T., Hornemann, S., Yaganoglu, S.,
Li, B., Herrmann, U, S., Wieland, B., Swayampakula, M., Rahman, M, H., Das, D., Kav, N., Riek,
R., Liberski, P, P., James, M, N., and A, A. (2013) The toxicity of antiprion antibodies is mediated
by the flexible tail of the prion protein, Nat. 501(7465), 102–6.
44. Heppner, F, L., Musahl, C., Arrighi, I., Klein, M, A., Rülicke, T., Oesch, B., Zinkernagel, R,
M., Kalinke, U., and A, A. (2001) Prevention of scrapie pathogenesis by transgenic expression of
anti-prion antibodies, Sci. 294(5540), 178–82.
45. Pfeifer, A., Eigenbrod, S., Al-Khadra, S., Hofmann, A., Mitteregger, G., Moser, M., Bertsch,
U., and Kretzschmar, H. (2006) Lentivector-mediated rnai efficiently suppresses prion protein and
prolongs survival of scrapie-infected mice, J Clin Invest 116(12), 3204–10.
46. Karapetyan, Y, E., Sferrazza, G, F., Zhou, M., Ottenberg, G., Spicer, T., Chase, P., Fallahi, M.,
Hodder, P., Weissmann, C., and Lasmézas, C, I. (2013) Unique drug screening approach for prion
diseases identifies tacrolimus and astemizole as antiprion agents, Proc Natl Acad Sci 110(17),
7044–9.
47. Triantaphyllidou, I, E., Sklaviadis, T., and Vynios, D, H. (2006) Detection, quantification, and
glycotyping of prion protein in specifically activated enzyme-linked immunosorbent assay plates,
Anal Biochem. 359(2), 176–82.
48. Maurel, D., Kniazeff, J., Mathis, G., Trinquet, E., Pin, J, P., and Ansanay, H. (2004) Cell surface
detection ofmembrane protein interactionwith homogeneous time-resolved fluorescence resonance
energy transfer technology, Anal Biochem. 329(2), 253–62.
49. Marella, M., Lehmann, S., Grassi, J., and Chabry, J. (2002) Filipin prevents pathological prion
protein accumulation by reducing endocytosis and inducing cellular prp release, J Biol Chem
277(28), 25457–64.
50. Magalhães, A, C., Silva, J, A., Lee, K, S., Martins, V, R., Prado, V, F., Ferguson, S, S., Gomez, M,
V., Brentani, R, R., and Prado, M, A. (2002) Endocytic intermediates involved with the intracellular
trafficking of a fluorescent cellular prion protein, J Biol Chem 277, 33311–8.
12
 at U
ZH
 H
auptbibliothek / Zentralbibliothek Zuerich on A
pril 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
TR-FRET assay to detect PrPC membrane expression and internalization rates
TABLES
Hpl PrnP-/- 0.25 0.5 1 2 4 8 16 32 64 128
ng/ml ng/ml ng/ml ng/ml ng/ml ng/ml ng/ml ng/ml ng/ml ng/ml
%CV 13.24 12.20 8.14 33.31 11.41 4.70 9.55 6.86 2.14 5.28 8.16
S/N 2.59 4.66 1.96 6.31 16.20 9.11 12.94 37.59 17.06 11.25
Z’ < 0.5 < 0.5 < 0.5 < 0.5 0.75 0.62 0.73 0.89 0.79 0.70
Hpl PrnP-/- 2 4 8 16 32 64 128 256 512 1024
µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml
%CV 37.69 35.63 40.17 37.65 30.59 17.77 14.05 10.94 9.62 7.87 6.71
S/N -0.09 -0.15 -0.01 0.90 1.40 2.50 3.43 5.49 7.91 10.76
Z’ < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 0.61
Table 1: Performance of the homogeneous FRET assay for recPrP (upper table) and PrPC from murine
N2aPK1 cell lysates (lower table). The assay was evaluated according to three parameters: coefficient of
variation (%CV), signal-to-noise ratio (S/N) and the Z’ factor. Acceptable values were: %CV values < 10%,
S/N > 8 and Z’ > 0.5.
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HTRF 32K 16K 8K 4K 2K 1K 0.5K 0.25K 0.13K 0.06K 0K
%CV 3.407 3.120 5.056 3.152 3.244 2.071 6.239 4.921 4.638 8.126 3.863
S/N 8.34 7.25 4.54 5.66 4.35 3.86 1.46 0.19 0.87 -0.18 0.00
Z’ 0.53 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5
TR 32K 16K 8K 4K 2K 1K 0.5K 0.25K 0.13K 0.06K 0K
%CV 13.02 7.216 6.609 7.330 7.043 16.54 11.19 23.16 47.96 64.86 82.06
S/N 7.59 13.66 14.89 13.42 13.77 5.83 7.73 3.50 1.63 1.01 0.00
Z’ 0.58 0.76 0.78 0.75 0.75 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5
HTRF 32K 16K 8K 4K 2K 1K 0.5K 0.25K 0.13K 0.06K 0K
%CV 2.421 1.114 3.400 7.895 2.051 5.153 5.177 2.767 11.97 3.086 3.863
S/N 22.0 30.3 12.9 4.63 9.29 3.69 1.15 0.95 -0.72 -2.16 0.00
Z’ 0.81 0.86 0.69 < 0.5 0.54 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5
TR 32K 16K 8K 4K 2K 1K 0.5K 0.25K 0.13K 0.06K 0K
%CV 8.190 5.421 5.856 11.18 7.243 8.366 23.43 63.48 64.15 62.31 82.11
S/N 11.9 16.9 14.2 7.71 6.67 3.69 1.54 0.58 -0.06 0.14 0.00
Z’ 0.70 0.77 0.71 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5
Table 2: Assay performance of the cell surface FRET assay in the HTRF mode (without washing steps) and
TR-FRET mode (after washing) in A549 (upper tables) and HeLa cells (lower tables) was assessed by three
parameters: coefficient of variation (%CV), signal-to-noise ratio (S/N) and the Z’ factor. Acceptable values
were: %CV values < 10%, S/N > 8 and Z’ > 0.5. K: cell number in thousands.
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TR-FRET assay to detect PrPC membrane expression and internalization rates
Abbreviation Description
AP2M1 Encodes the adaptor protein 2 (AP-2) which is involved in clathrin-dependent endocytosis
EHD1 Encodes the EH domain-containing protein 1, plays a role in endocytosis
GIT2 Encodes the ARF GTPase-activating protein GIT2
M6PR Encodes the mannose 6-phosphate receptor, interacts with AP1 clathrin adaptor complex
RAB5A G-protein, required for the fusion of plasma membrane and early endosomes
VPS28 Encodes the vacuolar protein sorting-associated protein 28 homolog, involved in endosomal sorting
of cell surface receptors
VPS35 Encodes the vacuolar protein sorting-associated protein 35 homolog, involved in retrograde trans-
port of proteins from endosomes to the trans-Golgi network
Table 3: Overview of the tested siRNAs on PrPC endocytosis rate and cell surface level. For the study of
PrPC endocytosis and cell surface expression, seven siRNAs acting in protein recycling pathways and their
downstream organelles were selected.
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PrPC cell surface expression PrPC endocytosis
mean ± SD (t0) normalized to untreated (t0) mean ± SD (t0-t30) endocytosis rate
untreated 448.43 ± 103.37 1 ± 0.23 213.62 ± 110.26 0.48 ± 0.36
PrP 229.24 ± 108.70 0.51 ± 0.24 52.65 ± 118.97 0.23 ± 0.63
AP2M1 443.52 ± 19.41 0.99 ± 0.04 40.64 ± 30.35 0.09 ± 0.07
EHD1 493.18 ± 28.72 1.10 ± 0.06 254.44 ± 80.13 0.52 ± 0.19
GIT2 459.97 ± 50.50 1.03 ± 0.11 228.70 ± 90.94 0.50 ± 0.25
M6PR 435.74 ± 82.25 0.97 ± 0.18 79.65 ± 102.08 0.18 ± 0.27
RAB5A 202.00 ± 89.66 0.45 ± 0.20 -51.60 ± 115.41 -0.26 ± 0.46
VPS28 349.60 ± 125.23 0.78 ± 0.28 199.25 ± 136.61 0.57± 0.59
VPS35 344.96 ± 122.54 0.77 ± 0.27 65.19 ± 137.30 0.19 ± 0.47
Table 4: Effect of siRNA treatment on PrPC cell surface expression and endocytosis rate. Left columns:
Influence of siRNA treatment on PrPC cell surface expression. Cells were incubated for three days with
siRNAs. PrPC cell surface level was detected with the POM2-Eu/POM2-APC antibody pair. PrPC cell
surface expression of siRNA treated cells is expressed as fold of untreated cells . Right columns: Influence
of siRNA treatment on the endocytosis rate of PrPC. Cells were incubated for three days with siRNAs and
labeled with POM2-Eu at 4 ºC. To induce endocytosis, cells were exposed to 37 ºC. At time point t0 = 0 min
and t1 = 30 min POM2-APC was added. The endocytosis rate was calculated as described in "experimental
procedures".
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FIGURES
Figure 1: Schematic representation of the antibody binding sites for PrP detection in the homogeneous
TR-FRET assay. The assay is based on the in-solution binding of two fluorophore-labeled POM antibodies
to identical or unique epitopes on PrP. POM antibodies were either labeled with Europium chelate (Eu) donor
fluorophore or APC-labeled acceptor. The antibody pairs POM2-Eu/POM2-APC (upper) POM2-Eu/3F4-
APC (middle) and POM2-Eu/POM1-APC (lower) were used in the assays. POM1 binds to alphahelix 1 in
the C-terminal globular domain, POM2 to the octapeptide repeats (residues 51-91, mouse sequence) in the
unfolded N-terminal part of PrP and 3F4 to the charged cluster (CC). The close proximity of the donor and
acceptor antibodies upon binding to PrP leads to a fluorescent TR-FRET signal at 665 nm after excitation at
320 nm, which is proportional to the PrP concentration. HC: hydrophobic core region.
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Figure 2: TR-FRET immunoassays for the detection of recombinant PrP and PrPC in crude cell lysates.
(A) Dilution range of recPrP using the antibody tandem pair POM1-Eu/POM2-APC. Recombinant PrP (128
- 0.125 ng/ml) was serially diluted in 1 mg/ml Hpl PrnP-/- cell lysate in polystyrene 384-well microtiter
plates and detected by TR-FRET. The sensitivity (lower detection limit, LDL) of the assay is < 0.125 ng/ml.
(B) Dynamic range of recPrP detection. The assay shows high linearity (R2 = 0.93) at concentrations of
0.5-8 ng/ml for the detection of recPrP. (C) Dilution range of PrPC in murine N2aPK1 cell lysates using the
antibody pair POM1-Eu/POM2-APC. Cells were lysed in RIPA buffer and serially diluted (1024 - 1 µg/ml)
in 1 mg/ml Hpl PrnP-/- cell lysate detected by TR-FRET. The sensitivity (lower detection limit, LDL) of
the assay is < 20 µg/ml of crude cell extract. (D) Dynamic range of PrPC detection. The assay shows a
high linearity (R2 = 0.92) in a concentration range between 500 to 30 µg/ml for the detection of PrPC. Each
dilution was performed in 10 replicate measurements (decuplicates). Error bars in the linear regression blots
represent the standard deviation (± SD) of 6 replicate measurements. Student’s t test: *: p < 0.05; **: p <
0.01; ***: p < 0.001; ****: p < 0.0001.
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TR-FRET assay to detect PrPC membrane expression and internalization rates
Figure 3: FRET immunoassay for the detection of PrPC on the cell surface of intact human cells. (A)
Schematic representation of the cell surface PrPC FRET detection assay. The FRET signal was assessed
either in the HTRF mode or after a washing step (TR-FRET mode) to remove unbound chromophore labeled
antibodies. (B and F) Cell number dilution range in HTRF mode. A549 and HeLa cells were serially diluted
(sextuplicates) in DMEM medium starting from 32’000 to 15 cells/well in polystyrene 384-well microtiter
plates. Hpl PrnP-/- cells were used as negative controls. (C and G) Linear range of PrPC cell surface detection
of A549 and HeLa cells in the HTRF mode, respectively. (D and H) Cell number dilution range of A549
and HeLa cells in TR-FRET mode. (E and I) Linear range of PrPC cell surface detection of A549 and HeLa
cells in the TR-FRET mode, respectively. Error bars represent the standard deviation (± SD) of 6 replicate
measurements. Student’s t test: *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001.
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Figure 4: Suitability test of the FRET immunoassay for the manipulation of PrP cell surface expression.
(A) Saturation binding curves of PrPC. A constant number of HeLa cells was incubated with unlabeled
POM2 antibody at different concentrations, followed by FRET signal detection with POM2-Eu/POM2-APC
in HTRF mode. (B) Saturation binding curves of PrPC after removing unbound POM-2 antibodies (TR-
FRET mode). (C-D) Release of cell surface PrPC by PI-PLC treatment. A constant number of A549 cells
was labeled with POM2-Eu/POM2-APC followed by PI-PLC digestion at various concentrations. PrPC cell
surface FRET signal was measured after PI-PLC treatment at the cell surface (C) as well as in the cell culture
medium (D). (E) Inhibition of PrPC cell surface expression by BFA treatment. A constant number of HeLa
cells was exposed to different BFA concentrations. PrPC cell surface expression was measured by POM2-
Eu/POM2-APC in the HTRF. (F) Same as (E), but in the TR-FRET mode. (G) siRNA mediated PRNP
knockdown. A549 cells were treated with different concentrations of PRNP siRNA and control siRNAs
for 3 days. PrPC cell surface expression was detected with the POM2-Eu/3F4-APC FRET antibody pair.
Scrambled and GAPDH siRNAs as well as Hpl PrnP-/- cells were used as negative and positive controls,
respectively. Error bars represent the standard deviation (± SD) of 6 replicate measurements. Student’s t
test: *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001.
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Figure 5: Principle of the endocytosis FRET immunoassay and detection of PrPC uptake by human cells.
(A) Schematic representation of the endocytosis FRET assay. PrPC on the cell surface is first labeled with
the donor FRET Eu-labeled antibody (t=0; 4 ºC). After removing excess antibody, cells are exposed to 37 ºC
to initiate the uptake of Eu-labeled cell-surface PrPC (t=1). During the course of internalisation Eu-labeled
cell-surface PrPC is endocytosed from the cell surface into the cell and residual Eu-labeled cell-surface PrPC
is measured by adding the acceptor FRET antibody at various time intervals (t=1-4). The endocytosis rate
of PrPC is calculated according to the uptake formula (see Experimental Procedures). (B) Time course of
PrPC endocytosis. A549 cells were first labeled with POM2-Eu at 4 ºC followed by the exposure to 37 ºC
to initiate the internalization of PrPC. At different time points (t=0 to 70 min) POM2-APC was added and
the Net-FRET of the remaining cell surface POM2-Eu labeled PrPC was measured. (C) Linear range of
PrPC internalization. Error bars represent the standard deviation (SD) of 6 replicate measurements. (D)
Determination of the internalization rate. The PrPC endocytosis index was calculated according to the
formula in Experimental Procedures and reached a half life time of about 25 min. (E) Time course of cell
surface PrPC. A549 cells were labeled with POM2-Eu/POM2-APC at 4 ºC followed by the exposure to 37
ºC. The Net-FRET of cell surface PrPC was measured at different time points.
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Figure 6: Effect of pharmaceutical compounds on PrPC endocytosis. (A) A constant number of A549
cells was pre-labeled with POM2-Eu and treated with various concentrations of chlorpromazine. After 30
minutes of incubation, PrPC endocytosis was assessed by the addition of POM2-APC. (B) Cell viability was
measured by the alamarBlue assay. (C) Same as (A), but for MbetaCD. (D) Same as (B), but for MbetaCD.
Error bars represent the standard deviation (± SD) of 6 replicate measurements. Student’s t test: *: p < 0.05;
**: p < 0.01; ***: p < 0.001; ****: p < 0.0001.
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Figure 7: Manipulation of PrPC endocytosis rate and cell surface expression by siRNA treatments. A549
cells were treated for three days with 50 nM siRNA. PrPC internalization (t0-t30) and cell surface expression
(t0) was measured by FRET using the antibody pair POM2-Eu/POM2-APC and the endocytosis rate (Table
4) was calculated according to the formula in Experimental Procedures. Untreated and PRNP siRNA treated
cells were used as controls. Error bars represent the standard deviation (± SD) of 6 replicate measurements.
Student’s t test: *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001.
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